Peptide
Tesamorelin

 

Tesamorelin

Tesamorelin is a growth hormone releasing hormone analog that increases IGF-1 levels in men and women, by an average of 181 micrograms/liter. It binds to and stimulates GHRH receptors with similar potency as endogenous GHRH. It has a host of other benefits including nootropic effects and reducing triglycerides. Tesamorelin has subsequently been shown to decrease carotid intima-media thickness (cIMT), visceral adipose tissue (VAT), and c-reactive protein (CRP). It has not been linked to significantly affect other pituitary hormones and their respective mechanisms in the body. Additionally, it can improve cognitive function for healthy seniors and patients with an increased risk of Alzheimer’s disease, due to mild cognitive impairment.

CLINICAL RESEARCH:

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
Treatment of HIV patients with daily tesamorelin, a growth hormone-releasing factor analogue, for 26 weeks resulted in a significant decrease in visceral adipose tissue (VAT) and improvement in lipids. The objective of the 26-week extension phase was to evaluate long-term safety and effects of tesamorelin. HIV patients with central fat accumulation in the context of antiretroviral therapy were randomized to tesamorelin 2 mg (n = 273) or placebo (n = 137) s.c. daily for 26 weeks. At week 26, patients originally on tesamorelin were rerandomized to 2 mg tesamorelin (T-T group, n = 154) or placebo (T-P group, n = 50), whereas patients originally on placebo were switched to tesamorelin (P-T group, n = 111). Safety included adverse events and glucose parameters. Tesamorelin was generally well tolerated. The prevalence of adverse events and serious adverse events during the extension phase was comparable with the initial phase. Changes in glucose parameters over 52 weeks were not clinically significant and similar to those after 26 weeks. The change in VAT was sustained at -18% over 52 weeks of treatment (P < 0.001 versus baseline) as was the change in triglycerides (-51 mg/dl, P < 0.001 versus baseline). Similar sustained beneficial effects were seen for total cholesterol, but high-density lipoprotein decreased minimally over 52 weeks. Upon discontinuation of tesamorelin, VAT reaccumulated. Treatment with tesamorelin was generally well tolerated and resulted in sustained decreases in VAT and triglycerides over 52 weeks without aggravating glucose. Though effects on VAT are sustained during treatment for 52 weeks, these effects do not last beyond the duration of treatment.

Contact us and discover
your new normal.

  • Date Format: MM slash DD slash YYYY
  • :
  • HOURS OF OPERATION
    Tuesday – Saturday: 10am-6pm
    Sunday – Monday: Closed

Contact us today to
schedule your consult!

Hormone Replacement Therapy

Take the guesswork out of balancing your hormones.

Custom plans at $179/mo

Thyroid Disorder Treatment

Reverse the effects of an age-related thyroid disorder.

Custom plans at $129/mo

Have more questions?

Contact us for a no-obligation consultation. Talk to a VitaHealth expert today.

888-481-8482

Menu